doi: 10.1111/j.1365-2249.2003.02392.x.
Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations
Affiliations
- PMID:15008984
- PMCID: PMC1808965
- DOI: 10.1111/j.1365-2249.2003.02392.x
Item in Clipboard
Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations
L J Walker et al. Clin Exp Immunol.2004 Mar.
Display options
Format
Display options
Format
Abstract
Anti-Saccharomyces cerevisiae antibodies (ASCAs) have been proposed as serological markers, which may differentiate Crohn's disease (CD) from ulcerative colitis (UC) and predict disease phenotype. Their importance in pathogenesis is unproven. We investigated the relationship between ASCAs, disease phenotype and NOD2/CARD15 genotype in CD and whether ASCAs were related to antibodies to other fungal proteins. Serum from 228 patients [143 CD, 75 UC, 10 with indeterminate colitis (IC)] and 78 healthy controls (HC) were assayed for ASCA. Antibodies (IgA, IgG) to other fungal proteins (Fusarium species ATC20334, Mycoprotein) were measured in the same samples using an in-house enzyme-linked immunosorbent assay (ELISA) assay. ASCAs were present in 57% of CD, 19% of UC, 30% of IC and 8% of HCs. ASCA-positive status was a predictor for CD with sensitivity of 57%, specificity of 87%, positive predictive value of 78% and negative predictive value of 68%. ASCA was associated with proximal (gastroduodenal and small bowel involvement) rather than purely colonic disease (P < 0.001) and with a more severe disease phenotype and requirement for surgery over a median follow-up time of 9 years (P < 0.0001). No associations with NOD2/CARD15 mutations were seen. There was no association between ASCA and antibodies to MP (IgA or IgG). These data implicate ASCA as a specific marker of disease location and progression in CD, emphasizing the heterogeneity within IBD.
Figures
ASCA as a disease marker. Column scatter plot of ASCA BI of patients in (a) all subject groups and (b) those with colonic CD, UC or IC. Dotted line denotes the ASCA BI cut-off value of 1. All values above the line are ASCA-positive. (a) Median ASCA BI: CD = 1·144, UC = 0·638, IC = 0·743, HC = 0·532. **ASCA BI of CD patients is significantly higher than all other groups (P < 0·001, Kruskal–Wallis). (b) Median ASCA BI: colonic CD = 0·824, UC = 0·638, IC = 0·743. *ASCA BI of colonic CD was significantly higher than that of UC or IC (P = 0·0031, Kruskal–Wallis).
Antibody titres to mycoprotein. Column scatter graphs of MP antibody titres for IgA (a) and IgG (b) in the different subject groups. Small bars denote median values. Antibody titres are in arbitrary units. (a) Median MP IgA titres: CD = 754, IC = 118, UC = 72·5, HC = 132. **MP IgA titre was significantly higher in CD compared with other subject groups (P < 0·001, Kruskal–Wallis). (b) Median MP IgG titres: CD = 50·4, IC = 44·0, UC = 238, HC = 47·2. **MP IgG titre was significantly higher in UC compared with other subject groups (P < 0·001, Kruskal–Wallis).
Similar articles
- Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, Foldi I, Lakos G, Tumpek J, Udvardy ML, Harsfalvi J, Fischer S, Lakatos L, Kovacs A, Bene L, Molnar T, Tulassay Z, Miheller P, Veres G, Papp J; Hungarian IBD Study Group; Lakatos PL.Papp M, et al.Inflamm Bowel Dis. 2007 Aug;13(8):984-92. doi: 10.1002/ibd.20146.Inflamm Bowel Dis. 2007.PMID:17417801
- New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J; Hungarian IBD Study Group; Lakatos PL.Papp M, et al.Am J Gastroenterol. 2008 Mar;103(3):665-81. doi: 10.1111/j.1572-0241.2007.01652.x. Epub 2007 Nov 28.Am J Gastroenterol. 2008.PMID:18047543
- CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.Cruyssen BV, Peeters H, Hoffman IE, Laukens D, Coucke P, Marichal D, Cuvelier C, Remaut E, Veys EM, Mielants H, De Vos M, De Keyser F.Cruyssen BV, et al.Clin Exp Immunol. 2005 May;140(2):354-9. doi: 10.1111/j.1365-2249.2005.02759.x.Clin Exp Immunol. 2005.PMID:15807862Free PMC article.
- HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature.Annese V, Piepoli A, Latiano A, Lombardi G, Napolitano G, Caruso N, Cocchiara E, Accadia L, Perri F, Andriulli A.Annese V, et al.Dis Colon Rectum. 2005 Jan;48(1):57-64; discussion 64-5. doi: 10.1007/s10350-004-0747-0.Dis Colon Rectum. 2005.PMID:15690658Review.
- From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health.Sendid B, Cornu M, Cordier C, Bouckaert J, Colombel JF, Poulain D.Sendid B, et al.Autoimmun Rev. 2024 Feb;23(2):103486. doi: 10.1016/j.autrev.2023.103486. Epub 2023 Nov 30.Autoimmun Rev. 2024.PMID:38040100Review.
Cited by
- Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Review.Da Cunha T, Vaziri H, Wu GY.Da Cunha T, et al.J Clin Transl Hepatol. 2022 Jun 28;10(3):531-542. doi: 10.14218/JCTH.2021.00344. Epub 2022 Jan 20.J Clin Transl Hepatol. 2022.PMID:35836773Free PMC article.Review.
- Diagnostic Value of ASCA and Atypical p-ANCA in Differential Diagnosis of Inflammatory Bowel Disease.Mokhtarifar A, Ganji A, Sadrneshin M, Bahari A, Esmaeilzadeh A, Ghafarzadegan K, Nikpour S.Mokhtarifar A, et al.Middle East J Dig Dis. 2013 Apr;5(2):93-7.Middle East J Dig Dis. 2013.PMID:24829676Free PMC article.
- Fungal feelings in the irritable bowel syndrome: the intestinal mycobiome and abdominal pain.van Thiel I, de Jonge W, van den Wijngaard R.van Thiel I, et al.Gut Microbes. 2023 Jan-Dec;15(1):2168992. doi: 10.1080/19490976.2023.2168992.Gut Microbes. 2023.PMID:36723172Free PMC article.Review.
- Current understanding of fungal microflora in inflammatory bowel disease pathogenesis.Underhill D, Braun J.Underhill D, et al.Inflamm Bowel Dis. 2008 Aug;14(8):1147-53. doi: 10.1002/ibd.20402.Inflamm Bowel Dis. 2008.PMID:18286647Free PMC article.Review.
- MICROBIOTA INSIGHTS IN CLOSTRIDIUM DIFFICILE INFECTION AND INFLAMMATORY BOWEL DISEASE.Rodríguez C, Romero E, Garrido-Sanchez L, Alcaín-Martínez G, Andrade RJ, Taminiau B, Daube G, García-Fuentes E.Rodríguez C, et al.Gut Microbes. 2020 Nov 9;12(1):1725220. doi: 10.1080/19490976.2020.1725220. Epub 2020 Mar 4.Gut Microbes. 2020.PMID:32129694Free PMC article.Review.
References
- Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther. 2000;14:1553–9. - PubMed
- Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24(Suppl.):2–6. - PubMed
- Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122:1242–7. - PubMed
- Shanahan F. Crohn's disease. Lancet. 2002;359:62–9. - PubMed
- Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol. 1999;11:648–56. - PubMed
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous